Xencor Reports Fourth Quarter And Full Year 2013 Financial Results
3/20/2014 6:11:53 AM
MONROVIA, Calif., March 19, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2013 and provided a review of business highlights.
Help employers find you! Check out all the jobs and post your resume.
comments powered by